Apoptosis, angiogenesis, inflammation, and oxidative stress: Basic interactions in patients with early and metastatic breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 6, 2012, Pages 999-1009

  Hamed, Enas A ^a   Zakhary, Madeha M ^a   Maximous, Doaa W ^b  

^a Assiut University Faculty of Medicine   (Egypt)

^b ASSIUT UNIVERSITY   (Egypt)

Author keywords

Angiogenesis; Apoptosis; Breast cancer; Cytokines; Oxidative stress

Indexed keywords

ESTROGEN RECEPTOR; FAS LIGAND; INTERLEUKIN 8; LIPID PEROXIDE; NITRIC OXIDE; PROTEIN BCL 2; SOLUBLE FAS LIGAND; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGE; APOPTOSIS; ARTICLE; BENIGN TUMOR; BREAST CANCER; BREAST TUMOR; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; EARLY CANCER; FEMALE; FIXED BREAST MASS; HUMAN; IMMUNOADSORBENT; INFLAMMATION; MAJOR CLINICAL STUDY; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); ONCOLOGICAL PARAMETERS; OXIDATIVE STRESS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TUMOR GROWTH;

ADULT; ANTIGENS, CD95; APOPTOSIS; BREAST NEOPLASMS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-8; LIPID PEROXIDES; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864353355     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1176-4     Document Type: Article

References (50)

1. Balbay MD, Pettaway CA, Kuniyasu H, Inoue K, Ramirez E, Li E, Fidler IJ, Dinney CP (1999) Highly metastatic human prostate cancer growing within the prostate of athymic mice over expresses vascular endothelial growth factor. Clin Cancer Res 5:783-789
2. Balkwill F (2002) Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13:135-141
3. Benoy IH, Salgado R, Van Dam P, Geboers K, VanMarck E, Scharpé S, Vermeulen PB, Dirix LY (2004) Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 10:7157-7162
4. Bukholm IK, Nesland JM, Karesn R, Jacobsen U, Borresendale AL (1997) Interaction between bcl-2 and p21 (WAF1/CIP1) in breast carcinomas with wild-type p53. Int J Cancer 73:38-41
5. De Larco JE, Wuertz BR, Yee D, Rickert BL, Furcht LT (2003) Atypical methylation of the interleukin-8 gene correlates strongly with the metastatic potential of breast carcinoma cells. Proc Natl Acad Sci USA 100:13988-13993
6. Ding AH, Nathan CF, Stuchr DJ (1988) Release of reactive nitrogen intermediate from mouse peritoneal macrophage comparison of activating cytokines and evidence for independent production. J Immuno 141(7):2407-2412
7. Donato NJ, Klostergaard J (2004) Distinct stress and cell destruction pathways are engaged by TNF and ceramide during apoptosis of MCF-7 cells. Exp Cell Res 294:523-533
8. Donskov F, Hokland M, Marcussen N, Torp Madsen HH, von der Maase H (2006) Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma-results from a randomized phase II trial. Br J Cancer 94:218-226
9. Gaballah HE, Abdel Salam I, Abdel Wahab N, Mansour OM (2001) Plasma bcl-2 and nitric oxide: possible prognostic role in patients with metastatic breast cancer. Med Oncol 18:171-178
10. Geller DA, Billiar TR (1998) Molecular biology of nitric oxide synthases. Cancer Metastasis Rev 17(1):7-23
11. Gönenç A, Erten D, Aslan S, Akinci M, Simşek B, Torun M (2006) Lipid peroxidation and antioxidant status in blood and tissue of malignant breast tumor and benign breast disease. Cell Biol Int 30(4):376-380
12. Gong Y, Sun X, Huo L (2005) Expression of cell adhesion molecules, CIM 4 s and Ecadherin, and microvessel density in invasive micropapillary carcinoma of the breast. Histopathology 46(1):24-30
13. Grau A, Codony R, Rafecas M, Barroeta AC, Guardiola F (2000) Lipid hydroperoxide determination in dark chicken meat through a ferrous oxidation-xylenol orange method. J Agric Food Chem 48(9):4136-4143
14. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR (2005) Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. Immunology 175(2):1197-1205
15. Haklar G, Sayin-Ozveri E, Yüksel M, Aktan AO, Yalçin AS (2001) Different kinds of reactive oxygen and nitrogen species were detected in colon and breast tumors. Cancer Lett 165(2):219-224
16. Jalava PJ, Collan YU, Kuopio T, Juntti-Patinen L, Kronqvist P (2000) Bcl-2 immunostaining: a way to finding unresponsive postmenopausal N? breast cancer patients. Anticancer Res 20(2B): 1213-1219
17. Jang J-H, Surh Y-J (2003) Potentiation of cellular antioxidant capacity by Bcl-2: implications for its antiapoptotic function. Biochem Pharmacol 66:1371-1379
18. Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441:431-436
19. Khanzode SS, Muddeshwar MG, Khanzode SD, Dakhale GN (2004) Antioxidant enzymes and lipid peroxidation in different stages of breast cancer. Free Radic Res 38:81-85
20. Kinipping E, Debatin KM, Stricker K, Heilig B, Eder A, Krammer PH (1995) Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemia. Blood 85:1562-1569
21. Kozlowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ (2003) Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst 48:82-84
22. Lala PK, Orucevic A (1998) Role of nitric oxide in tumor progression: lessons from experimental tumors. Cancer Metastasis Rev 17(1):91-106
23. Lang K, Niggeman B, Zanker K, Entschladen F (2002) Signal processing of migrating T24 human bladder carcinoma cells: role of the autocrine interleukin-8. Int J Cancer 99:673-680
24. Lee LF, Hellendall RP, Wang Y, Haskill JS, Mukaida N, Matsushima K, Ting JP (2000) IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J Immunol 164:2769-2775
25. Lee M, Hyun DH, Marshall KA, Ellerby LM, Bredesen DE, Jenner P, Halliwell B (2001) Effect of overexpression of BCL-2 on cellular oxidative damage, nitric oxide production, antioxidant defenses, and the proteasome. Free Radic Biol Med 31(12):1550-1559
26. Lin Y, Huang R, Chen L, Li S, Shi Q, Jordan C, Huang RP (2004) Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int J Cancer 109(4):507-515
27. Liu CY, Wang CH, Chen TC, Lin HC, Yu CT, Kuo HP (1998) Increased level of exhaled nitric oxide and up-regulation of inducible nitric oxide synthase in patients with primary lung cancer. Br J Cancer 78(4):534-541
28. McDonnell TJ, Korsmeyer SJ (1991) Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature 349:254-256
29. Mortensen K, Holck S, Christensen IJ, Skouv J, Hougaard DM, Blom J, Larsson LI (1999) Endothelial cell nitric oxide synthase in peritumoral microvessels is a favorable prognostic indicator in premenopausal breast cancer patients. Clin Cancer Res 5(5):1093-1097
30. Nahta R, Esteva FJ (2003) Bcl-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast cancer. Semin Oncol 30:143-149
31. Natoli G, Ianni A, Costanzo A, Petrillo GD, Ilari I, Chirillo P, Balsano C, Levrero M (1995) Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 11:1157-1164
32. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A (2001) Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 7:285-289
33. Pietenpol JA, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, Vogelstein B (1994) Paradoxical inhibition of solid tumor cell growth by bcl2. Cancer Res 54:3714-3717
34. Portakal O, Ozkaya O, Erden Inal M, Bozan B, Koşan M, Sayek I (2000) Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem 33:279-284
35. Rajneesh CP, Manimaran A, Sasikala KR, Adaikappan P (2008) Lipid peroxidation and antioxidant status in patients with breast cancer. Singap Med J 49(8):640
36. Sahebari M, Hatef MR, Rezaieyazdi Z, Abbasi M, Abbasi B, Mahmoudi M (2010) Correlation between serum levels of soluble Fas (CD95/Apo-1) with Disease Activity in Systemic Lupus Erythematosus Patients in Khorasan, Iran. Arch Iran Med 13(2):135-142
37. Sheen-Chen SM, Chen WJ, Eng HL, Chou FF (1997) Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Res Treat 43:211-215
38. Sheen-Chen SM, Chen HS, Eng HL, Chen WJ (2003) Circulating soluble Fas in patients with breast cancer. World J Surg 27:10-13
39. Suhendan E, Tang CH, Elizabeth AG (2005) NO news is not necessarily good news in cancer. Curr Cancer Drug Targets 5:103-115
40. Szlosarek PW, Balkwill FR (2003) Tumor necrosis factor alpha: a potential target for the therapy of solid tumors. Lancet Oncol 4(9):565-573
41. Thomadaki H, Scorilas A (2008) Molecular profile of the BCL-2 family of the apoptosis related genes in breast cancer cells after treatment with cytotoxic/cytostatic drugs. Connect Tissue Res 49:261-264
42. Thomsen LL, Miles DW, Happerfield LC, Bobrow LG, Knowles RG, Moncada S (1995) Nitric oxide synthase activity in human breast cancer. Br J Cancer 72:41-44
43. Thorburn A (2004) Death receptor-induced cell killing. Cell Signal 16:139-144
44. Uchara T, Kikuchi Y, Nonura Y (1999) Caspase activation accompanying cytochrome C release from mitochondria is possibly involved in nitric oxide-induced neuronal apoptosis in SH-SY5Y cells. J Neurochem 72:196-205
45. Ueno T, Toi M, Tominaga T (1999) Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res 5:3529-3533
46. Van Slooten HJ, Van de Vijiver MJ, Van de Velde CJ, van Dierendonck JH (1998) Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. Br J Cancer 77(5):789-796
47. Vargas-Roig LM, Cuello-Carrion FD, Fernandez-Escobar N, Daguerre P, Leuzzi M, Ibarra J, Gago FE, Nadin SB, Ciocca DR (2008) Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy. Mol Oncol 2:102-111
48. Xie K, Fidler IJ (1998) Therapy of cancer metastasis by activation of the inducible nitric oxide synthase. Cancer Metastasis Rev 17(1):55-75
49. Yang Q, Moran MS, Haffty BG (2009) Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy. Breast Cancer Res Treat 115:343-348
50. Zhao X, Sun X, Gao F, Luo J, Sun Z (2011) Effects of ulinastatin and docataxel on breast tumor growth and expression of IL-6, IL-8, and TNF-alpha. J Exp Clin Cancer Res 30:22